Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 208-704-1 | CAS number: 538-75-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Carcinogenicity
Administrative data
Description of key information
Weight of evidence. A 27-week carcinogenicity study was performed with the test item in female p53 haploinsufficient mice, NTP protocol (GLP study). No evidence of carcinogenic activity was found. A 20-week carcinogenicity study was also performed in female Tg.AC hemizygous mice, NTP protocol (GLP study). The test item gave a positive result in this study, but this result was not conclusive.
Key value for chemical safety assessment
Carcinogenicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via dermal route
Link to relevant study records
- Endpoint:
- carcinogenicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- January 5, 1999 - July 9, 1999.
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Reason / purpose for cross-reference:
- reference to other assay used for intermediate effect derivation
- Principles of method if other than guideline:
- Groups of 15 female p53 Haploinsufficient mice were dermally administered the test item at 6 concentrations for up to 27 weeks, and then necropsied and their organs examined histopathologically, in order to observe evidences of carcinogenic activity. NTP protocol.
- GLP compliance:
- yes
- Species:
- mouse
- Strain:
- other: B6.129-Trp53tmlBrd (N5)
- Remarks:
- p53 Haploinsufficient Mouse.
- Details on species / strain selection:
- The p53 haploinsufficient mouse model has been determined to be particularly useful for in vivo testing of mutagenic carcinogens [Donehower (1992); French (2001a,b), see 'Background material']: The heterozygous Trp53 null allele C57BL/6 (N5) mouse is susceptible to the rapid development of neoplasia by mutagenic carcinogens relative to control strains. This mouse model of chemical carcinogenesis demonstrates 1) dose-related rapid induction of tumors (26 wks), 2) multiple sites of carcinogen-specific tissue susceptibility, and 3) carcinogen-induced loss of heterozygosity involving the Trp53 wild-type allele or a p53 haploinsuficiency permitting mutation of other critical protooncogenes and/or inactivation of tumor suppressor genes driving tumorigenesis. Demonstration of mutation or loss of heterozygosity involving the Trp53 locus is consistent with a common finding in human cancers and supports extrapolation between rodents and humans.
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Taconic Farms, Inc. (Germantown, NY).
- Females nulliparous and non-pregnant: yes
- Age at study initiation: 8 weeks
- Housing: individually housed
- Diet: Irradiated NTP-2000 formula pelleted diet (Ziegler Brothers Inc., Gardners, PA), ad libitum.
- Water: ad libitum tap water (Washington Suburban Sanitary Comission Potomac Plant) via automatic watering system.
- Acclimation period: 2 weeks.
- Before the study began, 5 mice were randomly selected for parasite evaluation and gross observation for evidence of disease. Blood was collected from 5 randomly selected vehicle control mice. The sera were analyzed for antibody titers to rodent viruses; all results were negative.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3 ºC
- Humidity (%): 50 ± 15%
- Air changes (per hr): at least 10
- Photoperiod (hrs dark / hrs light): 12h/day
IN-LIFE DATES: From: January 5, 1999 (first dose) To: July 7-8, 1999 - Route of administration:
- dermal
- Vehicle:
- ethanol
- Details on exposure:
- TEST SITE
- Area of exposure: treatment was applied to center of a shaved dorsal area posterior of the scapulae to the base of the tail.
- % coverage: < 10%
TEST MATERIAL
- Dose formulations were prepared every 3 weeks by mixing the test item and anhydrous ethanol to give the required concentration. The dose formulations were stored in sealed vials under a headspace of inert gas for up to 35 days at room temperature, until April 1, 1999. Subsequent storage was performed at -20ºC.
- Concentration (if solution): 0, 0.75, 1.5, 3, 6, or 12 mg/kg bw.
- Constant volume or concentration used: yes
- For solids, paste formed: no
VEHICLE
- Justification for use and choice of vehicle (if other than water): the test item was moisture sensitive.
- Amount(s) applied (volume or weight with unit): 2 ml/kg bw. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Stability studies of 0.38, 2 and 7 mg/L dose formulations of lot 00920TZ were conducted by the study laboratory by GC. Stability was confirmed for up to 35 days at room temperature, in sealed containers under a nitrogen headspace, and for up to 3 hours when exposed to light and air at room temperature.
- Duration of treatment / exposure:
- 27 weeks.
- Frequency of treatment:
- 5 days per week.
- Dose / conc.:
- 0.75 mg/kg bw/day (nominal)
- Dose / conc.:
- 1.5 mg/kg bw/day (nominal)
- Dose / conc.:
- 3 mg/kg bw/day (nominal)
- Dose / conc.:
- 6 mg/kg bw/day (nominal)
- Remarks:
- Discontinued after 11 days due to the severity of skin lesions observed.
- Dose / conc.:
- 12 mg/kg bw/day (nominal)
- Remarks:
- Discontinued after 8 days due to the severity of skin lesions observed.
- No. of animals per sex per dose:
- 15
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: the doses for the study were based on the results of a 13-week toxicity study performed in B6C3F1 mice (see 'Cross-reference').
- Positive control:
- Not required.
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: clinical findings were recorded initially, weekly and at the end of the study.
DERMAL IRRITATION (if dermal study): Yes
- Time schedule for examinations:
BODY WEIGHT: Yes
- Time schedule for examinations: body weights were recorded initially, weekly and at the end of the study.
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: No
CLINICAL CHEMISTRY: No
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
- Necropsies were performed on all animals.
HISTOPATHOLOGY: Yes
- Tissues for microscopic examination were fixed and preserved in 10% neutral buffered formalin, processed and trimmed, embedded in paraffin, sectioned to a thickness of 4 to 6 μm, and stained with hematoxylin and eosin.
- Complete histopathologic examinations were performed on all animals.
- Tissues examined: in addition to gross lesions and tissue masses, adrenal gland, bone with marrow, kidney, liver, lung, lymph nodes (mandibular, mediastinal, and mesenteric), mammary gland, ovary, parathyroid gland, pituitary gland, skin, spleen, stomach (forestomach and glandular), thymus, thyroid gland, trachea, and uterus. - Clinical signs:
- no effects observed
- Dermal irritation (if dermal study):
- effects observed, treatment-related
- Description (incidence and severity):
- Chemical-related gross lesions of the skin at the site of application included reddening, red scars, red crusts, and ulcers. At the site of application, the incidences of focal chronic active inflammation of the dermis were increased in the 3 and 12 mg/kg groups, and the incidences of focal ulcer and focal chronic active inflammation of the subcutaneous tissue were increased in the 12 mg/kg group. In comparison, incidences of focal dermal chronic active inflammation, focal subcutaneous chronic active inflammation, focal epidermal hyperplasia, focal ulceration and focal sebaceous gland hyperplasia in the control site were less than those seen at the site of application and were less severe.
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- 12 animals died or were sacrificed moribund prior to the end of the study: 3 from the 3 mg/kg group, 1 from the 6 mg/kg group, 8 from the 12 mg/kg group.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Mean body weights of dosed groups were similar to those of the vehicle controls.
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No neoplasms were attributed to the administration of the test item. At the site of application, the incidences of focal epidermal hyperplasia were significantly increased in the 1.5, 3, and 12 mg/kg groups.
Myeloid cell hyperplasia of the bone marrow occurred in the 3 mg/kg or greater groups, and the incidence of this lesion was significantly increased in the 12 mg/kg group. Increased hematopoiesis can occur with inflammatory conditions due to the physiological need for more white blood cells. Therefore, the increased incidence of myeloid cell hyperplasia is considered a relative change in response to the skin lesions at the site of application. - Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- no effects observed
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 3 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- dermal irritation
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 6 mg/kg bw/day (nominal)
- System:
- integumentary
- Organ:
- skin
- Treatment related:
- yes
- Dose response relationship:
- yes
- Conclusions:
- Under test conditions, there was no evidence of carcinogenic activity of the test item.
- Executive summary:
A 27-week carcinogenicity study was performed with the test item in female p53 haploinsufficient mice (GLP study). Groups of 15 female mice were administered 0, 0.75, 1.5, 3. 6 or 12 mg/kg bw of test item in ethanol, 5 days per week for 27 weeks. Dosing of the 6 and 12 mg/kg groups was discontinued after 11 and 8 days due to the severity of skin lesions at the site of application. Twelve animals died or were sacrificed moribund prior to the end of the study: 8 from the 12 mg/kg group, 1 from the 6 mg/kg group, and 3 from the 3 mg/kg group. No neoplasms were attributed to the test item. Under the conditions of this 27 -week dermal study, there was no evidence of carcinogenic activity of the test item.
- Endpoint:
- carcinogenicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- June 15, 1995 - November 2, 1995.
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Reason / purpose for cross-reference:
- reference to other assay used for intermediate effect derivation
- Principles of method if other than guideline:
- Groups of 10 female Tg.AC hemizygous mice were dermally administered the test item at 6 concentrations for up to 20 weeks, and then necropsied and their organs examined histopathologically, in order to observe evidences of carcinogenic activity. NTP protocol.
- GLP compliance:
- yes
- Species:
- mouse
- Strain:
- FVB
- Remarks:
- FVB/N-TgN(v-Ha-ras)Led (Tg.AC) hemizygous mice.
- Details on species / strain selection:
- The Tg.AC hemizygous mouse model responds to both genoxotic and nongenotoxic carcinogens [Spalding (1999, 2000); Tennant (2001), see 'Background information']: The Tg.AC mouse carries an inducible v-Ha-ras oncogene that imparts the characteristic of genetically initiated skin to these animals. The induction of epidermall papillomas in the area of topically applied chemical agents, for duration of not more than 26 weeks, acts as a reporter of phenotype that defines the activity of the test article. The Tg.AC (v-Ha-ras) transgenic mouse model provides a reporter phenotype of skin papillomas in response to either genotoxic or nongenotoxic carcinogens.
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Taconic Laboratory Animals and Services, Inc. (Germantown, NY).
- Females nulliparous and non-pregnant: yes
- Age at study initiation: 6 weeks.
- Housing: individually housed
- Diet: ad libitum NIH-07 open formula pelleted diet (Ziegler Brothers Inc., Gardners, PA), changed weekly.
- Water: ad libitum tap water (Washington Suburban Sanitary Comission Potomac Plant) via automatic watering system.
- Acclimation period: 2 weeks.
- Before the study began, 5 mice were randomly selected for parasite evaluation and gross observation for evidence of disease. Blood was collected from 5 randomly selected vehicle control mice at study termination and from one mouse that was sacrificed moribund during the study. The sera were analyzed for antibody titers to rodent viruses; all results were negative.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3 ºC
- Humidity (%): 50 ± 15%
- Air changes (per hr): at least 10
- Photoperiod (hrs dark / hrs light): 12h/day - Route of administration:
- dermal
- Vehicle:
- ethanol
- Details on exposure:
- TEST SITE
- Area of exposure: treatment was applied to center of a shaved dorsal area posterior of the scapulae to the base of the tail.
- % coverage: < 10%
TEST MATERIAL
- Dose formulations were prepared every 3 weeks by mixing the test item and anhydrous ethanol to give the required concentration. The dose formulations were stored in sealed vials under a headspace of inert gas for up to 35 days at room temperature.
- Concentration (if solution): 0, 0.75, 1.5, 3, 6, or 12 mg/kg bw.
- Constant volume or concentration used: yes
- For solids, paste formed: no
VEHICLE
- Justification for use and choice of vehicle (if other than water): the test item was moisture sensitive.
- Amount(s) applied (volume or weight with unit): 2 ml/kg bw. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Stability studies of 0.38, 2 and 7 mg/L dose formulations of lot 00920TZ were conducted by the study laboratory by GC. Stability was confirmed for up to 35 days at room temperature, in sealed containers under a nitrogen headspace, and for up to 3 hours when exposed to light and air at room temperature.
- Duration of treatment / exposure:
- 20 weeks.
- Frequency of treatment:
- 5 days per week.
- Dose / conc.:
- 0.75 mg/kg bw/day (nominal)
- Dose / conc.:
- 1.5 mg/kg bw/day (nominal)
- Dose / conc.:
- 3 mg/kg bw/day (nominal)
- Dose / conc.:
- 6 mg/kg bw/day (nominal)
- Dose / conc.:
- 12 mg/kg bw/day (nominal)
- Remarks:
- Discontinued after 8 applications due to the severity of skin lesions observed.
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: the doses for the study were based on the results of 13-week toxicity studies performed in B6C3F1 mice (see 'Cross-reference').
- Positive control:
- Not required.
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: clinical findings were recorded initially, weekly and at the end of the study.
DERMAL IRRITATION (if dermal study): Yes
- Time schedule for examinations:
BODY WEIGHT: Yes
- Time schedule for examinations: body weights were recorded initially, weekly and at the end of the study.
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: No
CLINICAL CHEMISTRY: No
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
- Necropsies were performed on all animals. The heart, right kidney, liver, lung and thymus were weighed.
HISTOPATHOLOGY: Yes
- Tissues for microscopic examination were fixed and preserved in 10% neutral buffered formalin, processed and trimmed, embedded in paraffin, sectioned to a thickness of 4 to 6 μm, and stained with hematoxylin and eosin.
- Complete histopathologic examinations were performed on all vehicle control mice, all 12 mg/kg mice, and all mice that died before the end of the study. In addition, the skin was examined in all remaining dosed groups.
- Tissues examined: all gross lesions and tissue masses, plus adrenal gland, bone with marrow, brain, clitoral gland, esophagus, gallbladder, heart with aorta, large intestine (cecum, colon, rectum), small intestine (duodenum, jejunum, ileum), kidney, liver, lung, lymph nodes (mandibular and mesenteric), mammary gland, nose, ovary, pancreas, parathyroid gland, pituitary gland, salivary gland, skin, spleen, stomach (forestomach and glandular), thymus, thyroid gland, trachea, urinary bladder and uterus. - Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Clinical findings consisted of dose-related skin irritation at the site of the application in groups treated with 1.5 mg/kg or greater.
- Dermal irritation (if dermal study):
- effects observed, treatment-related
- Description (incidence and severity):
- Dose-related skin irritation at the site of the application in groups treated with 1.5 mg/kg or greater.
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- 13 animals died or were sacrificed moribund prior to the end of the study: 3 each from the vehicle control and 0.75 mg/kg groups, 4 from the 3 mg/kg group, 2 from the 6 mg/kg group, and 1 from the 12 mg/kg group. Overall, the survival was within the range known for the Tg.AC hemizygous mouse.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Mean body weights of dosed groups of mice were similar to those of the vehicle controls.
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- The absolute and relative weights of the liver in 1.5 mg/kg or greater mice were significantly greater than those in the vehicle controls.
- Gross pathological findings:
- no effects observed
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- At the site of application, the incidences of chronic active inflammation of the dermis and epidermal hyperplasia were significantly increased in the 3 and 6 mg/kg groups.
- Histopathological findings: neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- At the site of application, masses and/or nodules (papillomas) were observed: 0/10, 0/10, 1/10, 4/10, 6/10, 9/10 for the doses 0, 0.75, 1.5, 3, 6, 12, respectively. The incidences of squamous cell papilloma and multiplicity of squamous cell papiloma were increased in a dose-related manner. One squaomus cell carcinoma occured at the site of appication in a 6 mg/kg mouse.
- Other effects:
- no effects observed
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 3 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- histopathology: neoplastic
- histopathology: non-neoplastic
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 6 mg/kg bw/day (nominal)
- System:
- integumentary
- Organ:
- skin
- Treatment related:
- yes
- Dose response relationship:
- yes
- Conclusions:
- The test item gave a positive result in this study, due to a significant increase of squamous cell papilloma of the skin at the site of application. However, in the current study, it is not possible to determine how the test item induced papilloma with a dose response that was similar to that of irritation, inflammation, and hyperplasia at the site of application.
- Executive summary:
A 20-week carcinogenicity study was performed with the test item in female Tg.AC hemizygous mice (GLP study). Groups of 10 female mice were administered 0, 0.75, 1.5, 3. 6 or 12 mg/kg bw of test item in ethanol, 5 days per week for up to 20 weeks. Due to the severity of skin lesions, treatment was discontinued in the 12 mg/kg group after 8 applications. Although 13 animals died prior to the end of the study, no deaths related to the test item were observed, as the survival rate was within the acceptable range for the species. Incidences of chronic active inflammation of the dermis and epidermal hyperplasia were significantly increased in the 3 and 6 mg/kg groups. At the site of application, the incidences of squamous cell papilloma were increased in a dose-related manner. The test item gave a positive result in this study. However, in the current study, it is not possible to determine how the test item induced papilloma with a dose response that was similar to that of irritation, inflammation, and hyperplasia at the site of application.
Referenceopen allclose all
Table 1. Survival and Body Weights of Female p53 Mice.
Dose (mg/kg) |
Survival (a) |
Mean Body Weight (b) |
Final Weight Relative to Controls (%) |
||
Initial |
Final |
Change |
|||
0 |
15/15 |
18.6 ± 0.2 |
33.8 ± 1.2 |
15.3 ± 1.1 |
|
0.75 |
15/15 |
18.2 ± 0.3 |
32.1 ± 1.1 |
13.9 ± 1.1 |
95 |
1.5 |
15/15 |
18.3 ± 0.3 |
35.5 ± 1.2 |
17.2 ± 1.1 |
105 |
3 |
12/15 (c) |
18.5 ± 0.3 |
32.3 ± 1.3 |
13.8 ± 1.2 |
96 |
6 (d) |
14/15 (e) |
18.0 ± 0.3 |
32.0 ± 1.4 |
14.0 ± 1.2 |
95 |
12 (f) |
7/15 (g) |
18.1 ± 0.3 |
33.6 ± 2.4 |
15.5 ± 2.2 |
99 |
(a) Number of animals surviving at 27 weeks / number in group. (b) Weights and weight changes are given as mean ± standard error. Subsequent calculations are based on animals surviving to the end of the study. Differences from the vehicle control are not significant by Dunnett's test. (c) Week of death: 7, 10, 24. (d) Treatment was discontinued after 11 days due to the severity of skin lesions at the site of application. (e) Week of death: 5. (f) Treatment was discontinued after 8 days due to the severity of skin lesions at the site of application. (g) Week of death: 8, 9, 9, 9, 9, 9, 9, 10.
Table 2. Incidences of Nonneoplastic Lesions of the Skin (Site of Application).
|
Vehicle control |
0.75 mg/kg |
1.5 mg/kg |
3 mg/kg |
6 mg/kg (a) |
12 mg/kg (b) |
Number Microscopically Examined |
15 |
15 |
15 |
15 |
15 |
15 |
Dermis, Inflammation, Chronic Active, Focal (c) |
1 (1.0) (d) |
0 |
0 |
13** (1.3) |
2 (1.0) |
9 ** (3.3) |
Epidermis, Hyperplasia, Focal |
0 |
1 (1.0) |
5* (1.0) |
11** (1.5) |
1 (2.0) |
8** (3.0) |
Sebaceous Gland, Hyperplasia, Focal |
0 |
0 |
0 |
3 (1.7) |
0 |
3 (2.0) |
Ulcer, focal |
0 |
0 |
0 |
2 (4.0) |
1 (4.0) |
8** (3.9) |
Subcutaneous Tissue, Inflammation, Chronic Active, Focal |
0 |
0 |
0 |
2 (3.0) |
0 |
8 ** (3.6) |
* Significantly different (P≤0.05) from the vehicle control group by the Fisher exact test. ** P≤0.01. (a) Treatment was discontinued after 11 days because of the severity of skin lesions at the site of application. (b) Treatment was discontinued after 8 days because of the severity of skin lesions at the site of application. (d) Number of animals with lesion; Average severity grade of lesions in affected animals: 1 = minimal, 2 = mild, 3 = moderate, 4 = marked.
Table 2. Summary of the Incidence of Neoplasms in Female p53 Haploinsufficient Mice.
|
Vehicle control |
0.75 mg/kg |
1.5 mg/kg |
3 mg/kg |
6 mg/kg |
12 mg/kg |
Disposition Summary |
||||||
Animals initially in study |
15 |
15 |
15 |
15 |
15 |
15 |
Early deaths |
||||||
· Natural deaths |
|
|
|
1 |
1 |
1 |
· Moribund |
|
|
|
2 |
|
7 |
Survivors |
|
|
|
|
|
|
· Terminal sacrifice |
15 |
15 |
15 |
12 |
14 |
7 |
Animals examined microscopically |
15 |
15 |
15 |
15 |
15 |
15 |
Alimentary System |
||||||
Mesentery |
|
|
|
(1) |
|
|
· Lymphoma malignant |
|
|
|
1 (100%) |
|
|
Hematopoietic System |
||||||
Lymph node, mandibular |
(15) |
(15) |
(14) |
(14) |
(14) |
(14) |
· Histocytic sarcoma |
|
|
|
|
1 (7%) |
|
Lymph node, mesenteric |
(14) |
(15) |
(15) |
(15) |
(14) |
(14) |
· Histocytic sarcoma |
|
|
|
|
1 (7%) |
|
Lymph node, mediastinal |
(14) |
(15) |
(15) |
(12) |
(13) |
(13) |
· Histocytic sarcoma |
|
|
|
|
1 (8%) |
|
· Lymphoma malignant |
|
|
|
1 (8%) |
|
|
Thymus |
(15) |
(15) |
(15) |
(15) |
(14) |
(13) |
· Histocytic sarcoma |
|
|
|
|
1 (7%) |
|
· Lymphoma malignant |
|
|
|
1 (7%) |
|
|
Respiratory System |
||||||
Lung |
(15) |
(15) |
(15) |
(15) |
(14) |
(15) |
· Lymphoma malignant |
|
|
|
1 (7%) |
|
|
Systemic Lesions |
||||||
Multiple organs (b) |
(15) |
(15) |
(15) |
(15) |
(15) |
(15) |
· Histiocytic sarcoma |
|
|
|
|
1 (7%) |
|
· Lymphoma malignant |
|
|
|
1 (7%) |
|
|
Systems Examined with No Neoplasms Observed: Cardiovascular System Endocrine System General Body System Genital System Intergumentary System Musculoskeletal System Nervous System Special Senses System Urinary System |
||||||
Neoplasm Summary |
||||||
Total animals with primary neoplasms (c) |
|
|
|
1 |
1 |
|
Total primary neoplasms |
|
|
|
1 |
1 |
|
Total animals with malignant neoplasms |
|
|
|
1 |
1 |
|
Total malignant neoplasms |
|
|
|
1 |
1 |
|
Table 3. Summary of the Incidence of Nonneoplastic Lesions in Female p53 Haploinsufficient Mice.
|
Vehicle control |
0.75 mg/kg |
1.5 mg/kg |
3 mg/kg |
6 mg/kg |
12 mg/kg |
Disposition Summary |
||||||
Animals initially in study |
15 |
15 |
15 |
15 |
15 |
15 |
Early deaths |
||||||
· Natural deaths |
|
|
|
1 |
1 |
1 |
· Moribund |
|
|
|
2 |
|
7 |
Survivors |
|
|
|
|
|
|
· Terminal sacrifice |
15 |
15 |
15 |
12 |
14 |
7 |
Animals examined microscopically |
15 |
15 |
15 |
15 |
15 |
15 |
Alimentary System |
||||||
Liver |
(15) |
(15) |
(15) |
(15) |
(14) |
(15) |
· Hematopoietic cell proliferation |
|
|
|
|
|
1 (7%) |
· Hematopoietic cell proliferation, focal |
|
|
|
|
|
1 (7%) |
· Infiltration cellular, focal, lymphocyte |
|
1 (7%) |
|
4 (27%) |
1 (7%) |
2 (13%) |
· Inflammation, chronic active, focal |
|
|
|
|
|
1 (7%) |
· Hepatocyte, necrosis, focal |
4 (27%) |
6 (40%) |
5 (33%) |
4 (27%) |
2 (14%) |
1 (7%) |
· Periportal, vacuolization cytoplasmic, focal |
|
|
|
1 (7%) |
|
|
Stomach, glandular |
(15) |
(15) |
(15) |
(15) |
(14) |
(14) |
· Infiltration cellular, focal, lymphocyte |
|
|
|
1 (7%) |
|
|
Cardiovascular System: none |
||||||
Endocrine System |
||||||
Adrenal cortex |
(15) |
(15) |
(15) |
(15) |
(14) |
(13) |
· Subcapsular, hyperplasia |
|
|
|
|
|
1 (8%) |
· Subcapsular, hyperplasia, focal |
13 (89%) |
13 (87%) |
12 (80%) |
13 (87%) |
14 (100%) |
9 (69%) |
Thyroid gland |
(13) |
(15) |
(15) |
|
(13) |
(13) |
· Ectopic thymus |
|
2 (13%) |
3 (20%) |
1 (7%) |
1 (8%) |
|
· Inflammation, chronic active, focal |
1 (8%) |
|
|
|
|
|
General Body System: none |
||||||
Genital System |
||||||
Ovary |
(15) |
(15) |
(15) |
(15) |
(14) |
(14) |
· Atrophy |
|
|
1 (7%) |
|
|
1 (7%) |
Uterus |
(15) |
(15) |
(15) |
(15) |
(14) |
(14) |
· Endometrium, hyperplasia, cystic |
14 (93%) |
15 (100%) |
15 (100%) |
13 (87%) |
13 (93%) |
7 (50%) |
Hematopoietic System |
||||||
Bone marrow |
(15) |
(15) |
(15) |
(15) |
(14) |
(15) |
· Myeloid cell, hyperplasia |
|
|
|
3 (20%) |
1 (7%) |
8 (53%) |
Lymph node |
|
|
|
(1) |
|
|
· Inguinal, hyperplasia, lymphoid |
|
|
|
1 (100%) |
|
|
Lymph node, mandibular |
(15) |
(15) |
(14) |
(14) |
(14) |
(14) |
· Hyperplasia, lymphoid |
1 (7%) |
|
|
2 (14%) |
3 (21%) |
|
Lymph node, mediastinal |
(14) |
(15) |
(15) |
(12) |
(13) |
(13) |
· Hyperplasia, lymphoid |
|
|
1 (7%) |
|
|
|
Spleen |
(15) |
(15) |
(15) |
(15) |
(14) |
(14) |
· Hematopoietic cell proliferation |
15 (100%) |
15 (100%) |
15 (100%) |
15 (100%) |
13 (93%) |
13 (93%) |
· Pigmentation |
|
|
|
|
|
1 (7%) |
Thymus |
(15) |
(15) |
(15) |
(15) |
(14) |
(13) |
· Atrophy, diffuse |
|
|
|
|
|
2 (15%) |
· Atrophy, focal |
|
2 (13%) |
1 (7%) |
|
|
|
Intergumentary system |
||||||
Mammary gland |
(15) |
(15) |
(15) |
(15) |
(14) |
(14) |
· Inflammation, chronic active, focal |
|
|
|
|
|
1 (7%) |
Skin |
(15) |
(15) |
(15) |
(15) |
(15) |
(15) |
· Control, ulcer, focal |
|
|
|
1 (7%) |
|
2 (13%) |
· Dermis, epidermis, hyperplasia, focal |
|
|
|
|
|
1 (7%) |
· Dermis, control, inflammation, chronic active, focal |
|
|
|
3 (20%) |
1 (7%) |
2 (13%) |
· Dermis, skin, site of application, fibrosis |
|
|
|
|
|
1 (7%) |
· Dermis, skin, site of application, inflammation, chronic active, focal |
1 (7%) |
|
|
13 (87%) |
2 (13%) |
9 (60%) |
· Epidermis, control, hyperplasia, focal |
|
|
|
2 (13%) |
|
1 (7%) |
· Epidermis, skin, site of application, hyperplasia, diffuse |
|
|
1 (7%) |
2 (13%) |
|
|
· Epidermis, skin, site of application, hyperplasia, focal |
|
1 (7%) |
5 (33%) |
11 (73%) |
|
8 (53%) |
· Sebaceous gland, control, hyperplasia, focal |
|
|
|
1 (7%) |
|
1 (7%) |
· Sebaceous gland, skin, site of application, hyperplasia, focal |
|
|
|
3 (20%) |
|
3 (20%) |
· Skin, site of application, hyperkeratosis, diffuse |
|
|
|
1 (7%) |
1 (7%) |
|
· Skin, site of application, parakeratosis, focal |
|
|
|
1 (7%) |
1 (7%) |
|
· Skin, site of application, ulcer, focal |
|
|
|
2 (13%) |
1 (7%) |
8 (53%) |
· Subcutaneous tissue, control, inflammation, chronic active, focal |
|
|
|
1 (7%) |
|
2 (13%) |
· Subcutaneous tissue, skin, site of application, inflammation, chronic, focal |
|
|
|
|
1 (7%) |
|
· Subcutaneous tissue, skin, site of application, inflammation, chronic active, focal |
|
|
|
2 (13%) |
|
8 (53%) |
Musculoskeletal System: none |
||||||
Nervous System: none |
||||||
Respiratory System |
||||||
Lung |
(15) |
(15) |
(15) |
(15) |
(14) |
(15) |
· Alveolar epithelium, hyperplasia, focal |
|
|
1 (7%) |
|
|
|
· Alveolar epithelium, inflammation, chronic active, focal |
|
1 (7%) |
|
|
|
|
· Alveolus, inflammation, chronic active, focal |
1 (7%) |
|
|
|
1 (7%) |
1 (7%) |
· Perivascular, infiltration cellular, focal, lymphocyte |
1 (7%) |
|
|
|
2 (14%) |
|
Special Senses System: none |
||||||
Urinary System: |
||||||
Kidney |
(15) |
(15) |
(15) |
(15) |
(14) |
(14) |
· Infiltration cellular, focal, lymphocyte |
|
1 (7%) |
|
|
|
|
· Pelvis, infiltration cellular, focal, lymphocyte |
|
|
|
1 (7%) |
|
|
(a) Number of animals examined microscopically at the site and the number of animals with lesion.
Table 1. Survival and Body Weights of Females Tg.Ac Hemizygous Mice.
Dose (mg/kg) |
Survival (a) |
Mean Body Weight (b) |
Final Weight Relative to Controls (%) |
||
Initial |
Final |
Change |
|||
0 |
7/10 (c) |
20.6 ± 0.4 |
26.8 ± 1.5 |
6.0 ± 1.2 |
|
0.75 |
7/10 (d) |
20.9 ± 0.3 |
27.7 ± 1.0 |
7.1 ± 1.0 |
103 |
1.5 |
10/10 |
21.0 ± 0.4 |
26.7 ± 0.7 |
5.7 ± 0.7 |
100 |
3 |
6/10 (e) |
20.8 ± 0.3 |
27.5 ± 0.8 |
6.3 ± 0.8 |
103 |
6 |
8/10 (f) |
20.5 ± 0.4 |
28.8 ± 0.9 |
8.3 ± 0.7 |
108 |
12 (g) |
9/10 (h) |
20.5 ± 0.4 |
27.4 ± 0.9 |
27.4 ± 0.9 |
102 |
(a) Number of animals surviving at 20 weeks/number initially in group. (b) Weights and weight changes are given as mean ± standard error. Subsequent calulations are based on animals surviving to the end of the study. Differences from the vehicle control group are not significant by Dunnett's test. (c) Week of death: 9, 12, 15. (d) Week of death: 7, 12, 19. (e) Week of death: 8, 12, 14, 17. (f) Week of death: 11, 18. (g) Treatment was discontinued after 8 days because of the severity of skin lesions at the site of application. (h) Week of death: 11.
Table 2. Incidences of Neoplasms and Nonneoplastic Lesions of the Skin (Site of Application) in Female Tg.AC Hemizygous Mice.
|
Vehicle control |
0.75 mg/kg |
1.5 mg/kg |
3 mg/kg |
6 mg/kg |
12 mg/kg (a) |
No. Examined Macroscopically |
10 |
10 |
10 |
10 |
10 |
10 |
Dermis, Inflammation, Chronic Active (b) |
0 |
0 |
3 (1.7) (c) |
5* (1.8) |
8** (2.0) |
0 |
Epidermis, Hyperplasia |
0 |
0 |
0 |
6** (1.8) |
7** (2.0) |
1 (2.0) |
Squamous Cell Papilloma, Multiple |
0 |
0 |
1 |
0 |
3 |
5* |
Squamous Cell Papilloma (includes multiple) |
0 |
0 |
1 |
0 |
3 |
5* |
Squamous Cell Carcinoma |
0 |
0 |
0 |
0 |
1 |
0 |
*Significantly different (P ≤ 0.05) from the vehicle control group by the Fisher exact test. **P≤ 0.01. (a) Treatment was discontinued after 8 days because of the severity of skin lesions at the site of application. (b) Number of animals with lesion. (c) Average severity grade of lesions in affected animals: 1 = minimal, 2 = mild, 3 = moderate, 4 = marked.
Table 3. Summary of the Incidence of Neoplasms in Female Tg.AC Hemizygous Mice.
|
Vehicle control |
0.75 mg/kg |
1.5 mg/kg |
3 mg/kg |
6 mg/kg |
12 mg/kg |
Disposition Summary |
||||||
Animals initially in study |
10 |
10 |
10 |
10 |
10 |
10 |
Early deaths |
|
|
|
|
|
|
· Accidental death |
|
|
|
1 |
|
|
· Natural deaths |
1 |
1 |
|
1 |
|
1 |
· Moribund |
2 |
2 |
|
2 |
2 |
|
Survivors |
|
|
|
|
|
|
· Terminal sacrifice |
7 |
7 |
10 |
6 |
8 |
9 |
Animals examined microscopically |
10 |
10 |
10 |
10 |
10 |
10 |
Alimentary System |
||||||
Liver |
(10) |
(6) |
(6) |
(7) |
(10) |
(10) |
· Leukemia erythrocytic |
1 (10%) |
|
2 (33%) |
|
1 (10%) |
|
Pancreas |
(10) |
(3) |
|
(4) |
(2) |
(10) |
· Leukemia erythrocytic |
|
|
|
|
1 (50%) |
|
Stomach, forestomach |
(10) |
(4) |
(2) |
(5) |
(4) |
(10) |
· Squamous cell papilloma |
|
2 (50%) |
2 (100%) |
1 (20%) |
1 (25%) |
|
Tooth |
(4) |
(5) |
(6) |
(4) |
(5) |
(5) |
· Odontoma |
3 (75%) |
5 (100%) |
6 (100%) |
3 (75%) |
5 (100%) |
5 (100%) |
Endocrine System |
||||||
Thyroid gland |
(9) |
(4) |
|
(4) |
(2) |
(10) |
· C-cell, adenoma |
|
1 (25%) |
|
|
|
|
Hematopoietic System |
||||||
Lymph node |
|
(1) |
|
|
(1) |
|
· Leukemia erythrocytic |
|
|
|
|
1 (100%) |
|
Spleen |
(10) |
(5) |
(5) |
(4) |
(4) |
(10) |
· Leukemia erythrocytic |
|
|
2 (40%) |
|
1 (25%) |
|
Thymus |
(9) |
(3) |
|
(3) |
(2) |
(10) |
· Lymphoma malignant |
1 (11%) |
|
|
|
|
|
Intergumentary System |
||||||
Skin |
(10) |
(10) |
(10) |
(10) |
(10) |
(10) |
Squamous cell papilloma |
||||||
· Skin, site of application, · Squamous cell carcinoma |
|
|
1 (10%) |
|
|
1 (10%) |
· Skin, site of application, · Squamous cell carcinoma |
|
|
|
|
1 (10%) |
|
· Skin, site of application, · Squamous cell papilloma |
|
|
|
3 (30%) |
3 (30%) |
3 (30%) |
· Skin, site of application, · Squamous cell papilloma, multiple |
|
|
1 (10%) |
|
3 (30%) |
5 (50%) |
Systemic Lesions |
||||||
Multiple organs (b) |
(10) |
(10) |
(10) |
(10) |
(10) |
(10) |
· Lymphoma erythrocytic |
1 (10%) |
|
2 (20%) |
|
1 (10%) |
|
· Lymphoma malignant |
1 (10%) |
|
|
|
|
|
Systems Examined with No Neoplasms Observed: Cardiovascular System General Body System Genital System Musculoskeletal System Nervous System Respiratory System Special Senses System Urinary System |
||||||
Neoplasm Summary |
||||||
Total animals with primary neoplasms (c) |
5 |
6 |
9 |
6 |
8 |
10 |
Total primary neoplasms |
5 |
8 |
12 |
7 |
14 |
14 |
Total animals with benign neoplasms |
3 |
6 |
8 |
6 |
8 |
10 |
Total benign neoplasms |
3 |
8 |
10 |
7 |
12 |
14 |
Total animals with malignant neoplasms |
2 |
|
2 |
|
2 |
|
Total malignant neoplasms |
2 |
|
2 |
|
2 |
|
Table 4. Summary of Nonneoplastic Lesions in Female Tg.AC Hemizygous Mice.
|
Vehicle control |
0.75 mg/kg |
1.5 mg/kg |
3 mg/kg |
6 mg/kg |
12 mg/kg |
Disposition Summary |
||||||
Animals initially in study |
10 |
10 |
10 |
10 |
10 |
10 |
Early deaths |
|
|||||
· Accidental death |
|
|
|
1 |
|
|
· Natural deaths |
1 |
1 |
|
1 |
|
1 |
· Moribund |
2 |
2 |
|
2 |
2 |
|
Survivors |
|
|||||
· Terminal sacrifice |
7 |
7 |
10 |
6 |
8 |
9 |
Animals examined microscopically |
10 |
10 |
10 |
10 |
10 |
10 |
Alimentary system |
||||||
Gallbladder |
(9) |
(3) |
|
(3) |
(2) |
(7) |
· Inflammation |
|
1 (33%) |
|
|
|
1 (14%) |
Intestine large, rectum |
(9) |
(3) |
|
(4) |
(2) |
(9) |
· Anus, inflammation |
|
|
|
|
1 (50%) |
|
Liver |
(10) |
(6) |
(6) |
(7) |
(10) |
(10) |
· Fibrosis |
|
1 (17%) |
|
|
|
1 (10%) |
· Hematopoietic cell proliferation |
1 (10%) |
1 (17%) |
|
|
2 (20%) |
1 (10%) |
· Inflammation, chronic active, · focal |
|
3 (50%) |
3 (50%) |
4 (57%) |
6 (60%) |
2 (20%) |
· Inflammation, focal |
3 (30%) |
|
|
|
|
5 (50%) |
· Necrosis |
|
1 (17%) |
1 (17%) |
2 (29%) |
1 (10%) |
|
· Necrosis, focal |
1 (10%) |
|
|
|
|
1 (10%) |
Stomach, forestomach |
(10) |
(4) |
(2) |
(5) |
(4) |
(10) |
· Inflammation |
|
1 (25%) |
|
|
|
|
Stomach, glandular |
(10) |
(3) |
|
(4) |
(2) |
(10) |
· Inflammation |
1 (10%) |
|
|
|
|
1 (10%) |
· Serosa, fibrosis |
|
|
|
|
|
1 (10%) |
Tooth |
(4) |
(5) |
(6) |
(4) |
(5) |
(5) |
· Inflammation, chronic active |
|
|
|
|
|
1 (20%) |
Cardiovascular System |
||||||
Heart |
(10) |
(3) |
|
(4) |
(2) |
(10) |
· Inflammation, acute |
|
|
|
|
|
1 (10%) |
· Mineralization, focal |
|
|
|
|
|
1 (10%) |
Endocrine system |
||||||
Pituitary gland |
(10) |
(2) |
|
(3) |
(1) |
(8) |
· Pars distalis, necrosis, focal |
|
|
|
|
1 (10%) |
|
General Body System: none |
||||||
Genital System |
||||||
Clitoral gland |
(8) |
(1) |
|
(4) |
(1) |
(9) |
· Inflammation |
|
|
|
|
|
1 (11%) |
Uterus |
(10) |
(3) |
|
(4) |
(2) |
(10) |
· Cyst |
1 (10%) |
|
|
|
|
1 (10%) |
· Bilateral, cyst |
|
|
|
|
|
1 (10%) |
Hematopoietic System |
||||||
Bone marrow |
(10) |
(3) |
|
(4) |
(2) |
(10) |
· Hyperplasia |
3 (30%) |
|
|
2 (50%) |
1 (50%) |
2 (20%) |
· Myeloid cell, hyperplasia |
|
1 (33%) |
|
|
|
|
Lymph node |
|
(1) |
|
|
(1) |
|
· Bronchial, infiltration cellular, plasma cell |
|
1 (100%) |
|
|
|
|
Lymph node, mandibular |
(10) |
(3) |
(1) |
(4) |
(3) |
(10) |
· Hematopoietic cell proliferation |
|
1 (33%) |
|
|
|
|
· Infiltration cellular, histiocyte |
1 (11%) |
|
|
|
|
|
· Necrosis, focal |
1 (11%) |
|
|
1 (25%) |
|
|
Spleen |
(10) |
(5) |
(5) |
(4) |
(4) |
(10) |
· Fibrosis |
|
|
|
|
|
1 (10%) |
· Hematopoietic cell proliferation |
8 (80%) |
4 (80%) |
4 (80%) |
3 (75%) |
3 (75%) |
9 (90%) |
· Lymphoid follicle, depletion cellular |
|
|
|
|
|
1 (10%) |
Thymus |
(9) |
(3) |
|
(3) |
(2) |
(10) |
· Atrophy |
1 (11%) |
2 (67%) |
|
1 (33%) |
2 (100%) |
1 (10%) |
· Hemorrhage |
|
|
|
|
|
1 (10%) |
Intergumentary System |
||||||
Skin |
(10) |
(10) |
(10) |
(10) |
(10) |
(10) |
· Hemorrhage |
|
|
|
1 (10%) |
|
|
· Hyperplasia |
|
|
|
|
|
1 (10%) |
· Inflammation, chronic active |
|
|
1 (10%) |
|
|
|
· Dermis, inflammation |
|
|
|
|
1 (10%) |
|
· Dermis, inflammation, chronic active |
|
|
|
1 (10%) |
|
|
· Dermis, skin, site of application, · inflammation, chronic active |
|
|
3 (30%) |
5 (50%) |
8 (80%) |
|
· Epidermis, skin, site of application, hyperplasia |
|
|
|
6 (60%) |
7 (70%) |
1 (10%) |
Musculoskeletal System |
||||||
Bone |
(10) |
(3) |
|
(4) |
(2) |
(10) |
· Synovial tissue, inflammation |
1 (10%) |
|
|
|
|
|
Nervous System |
||||||
Brain |
(10) |
(3) |
|
(4) |
(2) |
(10) |
· Hemorrhage, acute |
|
|
|
1 (25%) |
|
|
Respiratory System |
||||||
Larynx |
|
|
|
|
|
(1) |
· Inflammation |
|
|
|
|
|
1 (10%) |
Lung |
(10) |
(3) |
|
(4) |
(2) |
(10) |
· Hemorrhage, acute |
|
|
|
1 (25%) |
|
|
· Inflammation, chronic active |
|
|
|
|
|
4 (40%) |
Nose |
(10) |
(3) |
|
(4) |
(5) |
(10) |
· Inflammation |
|
|
|
|
3 (60%) |
1 (10%) |
· Respiratory epithelium, inflammation |
|
|
|
|
|
1 (10%) |
Special Senses System: none |
||||||
Urinary System |
||||||
Kidney |
(10) |
(3) |
|
(4) |
(2) |
(10) |
· Inflammation, chronic active |
|
1 (33%) |
|
|
|
1 (10%) |
· Bilateral, inflammation |
|
|
|
|
|
1 (10%) |
· Cortex, cyst |
1 (10%) |
|
|
|
|
|
(a) Number of animals examined microscopically at the site and the number of animals with lesion.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Study duration:
- chronic
- Species:
- mouse
- Quality of whole database:
- Two studies available, with a Klimisch score of 2.
Justification for classification or non-classification
Based on the available information, the substance is not classified for carcinogenicity according to CLP Regulation (EC) no. 1272/2008.
Additional information
Weight of evidence. A 27-week carcinogenicity study was performed with the test item in female p53 haploinsufficient mice (GLP study). Groups of 15 female mice were administered 0, 0.75, 1.5, 3. 6 or 12 mg/kg bw of test item in ethanol, 5 days per week for 27 weeks. Dosing of the 6 and 12 mg/kg groups was discontinued after 11 and 8 days due to the severity of skin lesions at the site of application. No neoplasms were attributed to the test item. Under the conditions of this 27 -week dermal study, there was no evidence of carcinogenic activity of the test item. A 20-week carcinogenicity study was also performed, with the test item in female Tg.AC hemizygous mice (GLP study). Groups of 10 female mice were administered 0, 0.75, 1.5, 3. 6 or 12 mg/kg bw of test item in ethanol, 5 days per week for up to 20 weeks. Due to the severity of skin lesions, treatment was discontinued in the 12 mg/kg group after 8 applications. Although 13 animals died prior to the end of the study, no deaths related to the test item were observed, as the survival rate was within the acceptable range for the species. Incidences of chronic active inflammation of the dermis and epidermal hyperplasia were significantly increased in the 3 and 6 mg/kg groups. At the site of application, the incidences of squamous cell papilloma were increased in a dose-related manner. The test item gave a positive result in this study. However, in the current study, it is not possible to determine how the test item induced papilloma with a dose response that was similar to that of irritation, inflammation, and hyperplasia at the site of application.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.